My watch list  


Systematic (IUPAC) name
phenyl]oxazolidin-5-yl]methyl] thiophene-2-carboxamide
CAS number 366789-02-8
ATC code  ?
PubChem 6433119
Chemical data
Formula C19H18ClN3O5S 
Mol. mass 435.882
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life 5.7-9.2
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status


Routes oral

Rivaroxaban (BAY 59-7939) is an oral anticoagulant under development by Bayer; it will be marketed as Xarelto. It acts by inhibiting the active form of coagulation factor X (factor Xa).



Rivaroxaban is an oxazolidinone derivative optimised for binding with factor Xa.[1] If marketed, it will be a joint product by Bayer and Ortho-McNeil Pharmaceutical.[2]



Due to the decreased need for monitoring, rivaroxaban is likely to be used to replace warfarin for a number of indications, such as atrial fibrillation.[3]

Trial results

In phase IIb trials it was effective in reducing thromboembolic complications (deep vein thrombosis and pulmonary embolism) after orthopedic surgery[4] and it is under investigation for the treatment of DVT and PE and for anticoagulation in atrial fibrillation.[3] Advantages are the oral administration (a benefit over low molecular weight heparins, which require subcutaneous injections) and no need for monitoring (an advantage over warfarin). In studies, dosages of 2.5-10 mg once or twice daily were used.[4]

On July 8, 2007, Bayer sponsored Phase 3 clinical trial data showing once-daily rivaroxaban achieved superior efficacy in the prevention of venous thromboembolism (VTE) in patients undergoing knee replacement surgery in comparison with enoxaparin, a LMWH.[5]

Related drugs

Ximelagatran, a direct thrombin inhibitor, was not marketed further due to its potential side-effects; the related compound dabigatran is undergoing studies. Together with rivaroxaban, the related factor Xa-inhibitor apixaban (Bristol-Myers-Squibb) and LY517717 (Lilly) are under development as non-monitored antithrombotic drugs.[6]


  1. ^ Roehrig S, Straub A, Pohlmann J, et al (2005). "Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor". J. Med. Chem. 48 (19): 5900–8. doi:10.1021/jm050101d. PMID 16161994.
  2. ^ Bayer, Ortho-McNeil to co-develop key thrombosis drug. Retrieved on 2007-12-03.
  3. ^ a b Clinical trial NCT00403767
  4. ^ a b Eriksson BI, Borris L, Dahl OE, et al (2006). "Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement". J. Thromb. Haemost. 4 (1): 121–8. doi:10.1111/j.1538-7836.2005.01657.x. PMID 16409461.
  5. ^ The Bayer HealthCare Press Club (2007-07-08). "Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery". Press release. Retrieved on 2007-12-03.
  6. ^ Hampton T (2006). "New oral anticoagulants show promise.". JAMA 295 (7): 743–4. doi:10.1001/jama.295.7.743. PMID 16478891.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rivaroxaban". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE